Esperion Therapeutics, Inc. ESPR 深 沪
等待开盘 03-26 09:30:00 美东时间
2.76
+0.140
+5.34%
华盛通- 最 高2.86
- 今 开2.67
- 成交量 458.99万股
- 最 低 2.66
- 昨 收 2.62
- 总市值 6.60亿
- 52周最高 4.175
- 市盈率 静 --
- 换手率 1.92%
- 52周最低 0.6925
- 委 比 17.30%
- 总股本 2.39亿
- 历史最高 120.96
- 量 比 1.01
- 振 幅 7.63%
- 历史最低 0.6925
- 每 手 1
- 风险率 1.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed outlook on top names: Adobe cut to $280, ServiceTitan to $100, KinderCare cut to $1.5, Nio upgraded to $6.8, Esperion raised to $5, Flagstar raised to $16, Nerdwallet cut to $9, Erasca raised.
03-13 20:09
Citizens Maintains Market Outperform on Esperion Therapeutics, Raises Price Target to $5
Citizens analyst Jason N. Butler maintains Esperion Therapeutics (NASDAQ:ESPR) with a Market Outperform and raises the price target from $4 to $5.
03-13 18:36
Esperion shares are trading lower after the company reported worse-than-expected Q4 financial results.
Esperion shares are trading lower after the company reported worse-than-expecte...
03-11 02:03
Earnings Scheduled For March 10, 2026
Companies Reporting Before The Bell • Ultralife (NASDAQ:ULBI) is likely to repo...
03-10 19:11
Insights into Esperion Therapeutics Q4 Earnings
Esperion Therapeutics (NASDAQ:ESPR) announced its Q4 earnings on Tuesday, March...
03-10 18:02
Esperion Therapeutics Q4 EPS $0.22 Misses $0.30 Estimate, Sales $168.446M Miss $174.519M Estimate
Esperion Therapeutics (NASDAQ:ESPR) reported quarterly earnings of $0.22 per share which missed the analyst consensus estimate of $0.30 by 25.68 percent. This is a 300 percent increase over losses of $(0.11) per share
03-10 18:01
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
Needham Maintains Buy on Esperion Therapeutics, Raises Price Target to $5
Needham analyst Serge Belanger maintains Esperion Therapeutics (NASDAQ:ESPR) with a Buy and raises the price target from $4 to $5.
03-04 02:32
Esperion Acquires Enbumyst Maker Corstasis
Esperion (ESPR) shares dip premarket after announcing a $75M deal to buy Corstasis Therapeutics, adding FDA-approved nasal spray Enbumyst.
03-03 21:25
